Amoy Diagnostics Receives NMPA Approval for MSI Detection Kit as Companion Diagnostic for Immunotherapy
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in the Chinese diagnostics industry,...
BeiGene
BeiGene’s Brukinsa Gains NICE Recommendation for CLL Treatment in the UK
China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National...
BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC
China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...
BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...
BeiGene’s Brukinsa Receives Positive CHMP Opinion for Follicular Lymphoma Treatment
China-based biotechnology leader BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the receipt of...
China’s NHC Expands Rare Disease List, Includes 21 Cancer Types
The National Health Commission (NHC) of China has released an updated national list of rare...
BeiGene Regains Full Rights to Tislelizumab After Terminating Novartis Deal
China-based biotech company BeiGene (NASDAQ: BGNE) has reached a mutual agreement with Novartis (NYSE: NVS)...
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...
Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth
China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...
BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023
BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...
Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...
BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...
BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA
China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...
Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...